A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant. (March 2017)

• Record Type: Journal Article
• Authors: Davis, Ian D; Quirk, Juliet; Morris, Leone; Seddon, Lauren; Tai, Tsin Yee; Whitty, Genevieve; Cavicchiolo, Tina; Ebert, Lisa; Jackson, Heather; Browning, Judy; MacGregor, Duncan; Wittke, Frederick; Winkels, Gregor; Alex, Regina; Miloradovic, Lena; Maraskovsky, Eugene; Chen, Weisan; Cebon, Jonathan
• Is Part Of: Immunotherapy. Volume 9:Number 3(2017)
• Page Start: 249
• Page End: 259
• Publication Date: 2017-03
• Subjects: antigens -- clinical trial -- dendritic cells -- ISCOMATRIX™ adjuvant -- NY-ESO-1; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2016-0132
• Languages: English
• ISSNs: 1750-743X

Abstract

Aim: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses.Patients & methods: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS ® plus, with initial depletion of CD1c + B cells followed by positive selection of CD1c + PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals.Results: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission.Conclusion: This method was feasible and safe but was minimally immunogenic.